SLC5A2 and hydrops fetalis: The results of this systematic review and meta-analysis demonstrated the benefit of SGLT2 inhibitors for significantly reducing the risk of the composite of CV death, HHF, or urgent visit for HF compared to placebo in patients with HFmrEF or HFpEF, but their benefit for reducing CV death alone and all-cause death alone could not be established.